Akeso’s lung cancer drug beat world best-selling drug, a biotech DeepSeek watershed

Akeso

What happened?

In the fall of 2024, a watershed event occurred in the biotech industry. At that time, Summit Therapeutics (ticker: SUMT) announced that Ivonescimab, a new cancer immunotherapy drug licensed from Akeso (HK stock code: 9926), performed better than Merck’s (ticker: MSD) star drug Keytruda in treating patients with advanced lung cancer.

A biotech watershed

Some people compare this to the biotech version of China’s generative artificial intelligence DeepSeek shocking Silicon Valley. Because Keytruda is not only the global drug sales champion, but also Merck’s golden goose. This is the first time that a new drug from China’s biotech industry has defeated the US biotech pharmaceutical industry, which has long dominated the global biotech industry.

Akeso

Relative articles

Disclaimer

  • The content of this site is the author’s personal opinions and is for reference only. I am not responsible for the correctness, opinions, and immediacy of the content and information of the article. Readers must make their own judgments.
  • I shall not be liable for any damages or other legal liabilities for the direct or indirect losses caused by the readers’ direct or indirect reliance on and reference to the information on this site, or all the responsibilities arising therefrom, as a result of any investment behavior.
error: Content is protected !!